TUESDAY, OCTOBER 17, 2017

GlaxoSmithKline announces changes in leadership

Changes in GSK committee and board
Changes in GSK committee and board | Courtesy of gsk.com
GlaxoSmithKline PLC (GSK) has announced Manvinder Singh (Vindi) Banga will be the non-executive director of GSK’s board, effective Sept. 1.

From 1977 to 2010, Banga served Unilever PLC in several positions, most recently as president of the Global Foods, Home & Personal Care businesses. He also served as a member of Unilever's executive board. Currently, he is a partner with the private equity fund Clayton, Dubilier & Rice. He is also the chairman of the supervisory board of Mauser Group. With Marks & Spencer Group, he is the senior independent director, and he's the non-executive director of Thomson Reuters Corp.

Sir Deryck Maughan is Banga’s predecessor as the senior independent director. Banga will assume these additional duties on May 5, 2016, as Maughan will not run for re-election to GSK’s board during the 2016 annual general meeting.

“I am delighted that Vindi is joining the Board,” Sir Philip Hampton, chairman designate, said. “Vindi brings with him many years of experience and a track record of delivering outstanding performance in a highly competitive global consumer-focused industry which will be invaluable to GSK. My colleagues and I very much look forward to welcoming him to the Board.”

In addition, GSK has named Urs Rohner the chairman of the Renumeration Committee and Lynn Elsenhans chairman of the Corporate Responsibility Committee.